Zhuoxing Li

Zhuoxing Li

Auto-generated profile, based on publicly available information

Zhuoxing Li

Department of Clinical Medicine, Chengdu Medical College, Chengdu, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2025 in medRxiv
Verified
Preprint
Open access
PDF file
XDXi Du
Xi Du
QYQianyu Yang
Qianyu Yang
ZDZhiqiang Duan
Zhiqiang Duan
HGHui Gu
Hui Gu
XZXue Zhang
Xue Zhang
XXXiang Xiao
Xiang Xiao
Objective: This study aims to investigate the prevalence of osteoporosis (OS) in patients with Cardiovascular Kidney Metabolic (CKM) Syndrome and its relationship with the risk of mortality in CKM patients. Methods: Patients diagnosed with CKM were included from the National Health and Nutrition Examination Survey database between 2009 and 2018. The primary endpoint was all-cause mortality, while the secondary endpoint was cardiovascular mortality. The relationship between OS and the prognosis of all-cause mortality and cardiovascular mortality in CKM patients was assessed using Kaplan-Meier survival curves and multivariate Cox regression model. Results: A total of 602 Non-CKM (stage 0) and 6129 CKM (stages 1, 2, 3, and 4) patients were included. The prevalence of OS in CKM patients at stages 0, 1, 2, 3, and 4 was 3.49%, 2.25%, 4.97%, 13.52%, and 8.39%, respectively. The multivariate Cox regression analysis revealed that compared to the normal bone mineral density group, CKM patients in the osteopenia group had a 55% increased risk of all-cause mortality (HR=1.55; 95% CI, 1.22-1.98, P = 0.001) and a 120% increase in the risk of cardiovascular mortality (HR=2.20; 95% CI, 1.39-3.46, P = 0.001); In the OS group, CKM patients exhibited a 199% increased risk of all-cause mortality (HR = 2.99; 95% CI, 1.86-4.82, P = 0.001) and a 2.14-fold increase in the risk of cardiovascular mortality (HR=3.14; 95% CI, 1.09-9.02, P = 0.03). Conclusion: Osteopenia and OS are more prevalent in patients with CKM and are associated with an increased risk of all-cause and cardiovascular mortality.

25 March 2026 in Kidney Research and Clinical Practice
Verified
Journal Article
Closed access
XLXiunan Liu
Xiunan Liu
ZLZhuoxing Li
Zhuoxing Li
HLHao Liu
Hao Liu
MXMao Xiao
Mao Xiao
XZXue Zhang
Xue Zhang
XXXiang Xiao
Xiang Xiao
Medical nutrition therapy serves as the cornerstone in the management of chronic kidney disease (CKD). While conventional approaches emphasize macronutrient restriction and meal timing adjustments, research highlights the critical mediating role of gut microbiota in translating dietary patterns into physiological effects through metabolite production. Meanwhile, CKD progression is closely associated with dynamic interactions between gut microbiota and their metabolic derivatives. This review introduces the "diet-microbiota- metabolite-kidney axis" framework to elucidate how nutritional components modulate CKD progression via microbial compositional changes and subsequent metabolite alterations. Based on synthesized evidence, this review identifies promising directions for precision nutrition strategies targeting microbial metabolites, including artificial intelligence-assisted dietary planning, engineered bacterial therapies, and metabolite analog development. However, significant interindividual variability in host genetics and baseline microbiota composition necessitates overcoming heterogeneity challenges in nutritional interventions. Consequently, the precise modulation of individualized diet-microbiota-metabolite interactions represents a critical research direction to be prioritized in CKD management.